Изучение спинальной мышечной атрофии 2 типа с позиции особенности онтогенеза

Соколова Мария Георгиевна · Universum · 2015

Results of complex clinical laboratory research of 12 patients with spinal muscular atrophy of II type are presented in the article. Spinal muscular atrophy of II type is autosomal-recessive disease characterized by alfa-motor neuron degenerative changes of anterior horns. The disease is manifested in weakness of proximal muscles, paresis, respiratory distress and early death. It is identified that blood serum of patients with spinal muscular atrophy of II type has statistically-valid enhanced concentration of neurotrophins — brain growth promoting substance and nerve growth factor. This disease refers to the group of system atrophy damaging mainly central nervous system and occurs in children. At the same time in patients with amyotrophic lateral sclerosis, the disease also refers to this group but is diagnosed in adults; according to literature, impoverishment of neurotrophins (brain growth promoting substance, nerve growth factor) is marked in the process of disease progression. The assumption is made that data of neurotrophin concentration change is connected with peculiarities of patients’ infancy with spinal muscular atrophy of II type. Revealed characteristics of neurotrophic regulation in spinal muscular atrophy of II type must be taken into account when curing patients with this pathology. The therapy of patients with spinal muscular atrophy of II type must not be focused on extra stimulation of tyrosine receptors through which brain growth promoting substance and nerve growth factor act.

Cited by 0 works.

Authors